Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Role of ANA testing in the classification of patients with systemic lupus erythematosus.

Pisetsky DS, Spencer DM, Rovin B, Lipsky PE.

Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216259. doi: 10.1136/annrheumdis-2019-216259. [Epub ahead of print] No abstract available.

PMID:
31540932
2.

Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May 10. pii: annrheumdis-2019-215479. doi: 10.1136/annrheumdis-2019-215479. [Epub ahead of print] No abstract available.

PMID:
31076389
3.

Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.

Collinson-Pautz MR, Chang WC, Lu A, Khalil M, Crisostomo JW, Lin PY, Mahendravada A, Shinners NP, Brandt ME, Zhang M, Duong M, Bayle JH, Slawin KM, Spencer DM, Foster AE.

Leukemia. 2019 Sep;33(9):2195-2207. doi: 10.1038/s41375-019-0417-9. Epub 2019 Feb 28.

4.

Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches.

Duong MT, Collinson-Pautz MR, Morschl E, Lu A, Szymanski SP, Zhang M, Brandt ME, Chang WC, Sharp KL, Toler SM, Slawin KM, Foster AE, Spencer DM, Bayle JH.

Mol Ther Oncolytics. 2018 Dec 20;12:124-137. doi: 10.1016/j.omto.2018.12.009. eCollection 2019 Mar 29.

5.

Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jan 18. pii: annrheumdis-2018-214829. doi: 10.1136/annrheumdis-2018-214829. [Epub ahead of print] No abstract available.

PMID:
30659048
6.

Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin B.

Ann Rheum Dis. 2018 Dec 1. pii: annrheumdis-2018-214766. doi: 10.1136/annrheumdis-2018-214766. [Epub ahead of print] No abstract available.

PMID:
30504443
7.

Response to: 'ANA testing in "real life"' by Infantino et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Nov 17. pii: annrheumdis-2018-214650. doi: 10.1136/annrheumdis-2018-214650. [Epub ahead of print] No abstract available.

PMID:
30448767
8.

Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Aug;78(8):e77. doi: 10.1136/annrheumdis-2018-213841. Epub 2018 Jun 23. No abstract available.

PMID:
29936440
9.

Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e51. doi: 10.1136/annrheumdis-2018-213582. Epub 2018 May 5. No abstract available.

PMID:
29730639
10.

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e49. doi: 10.1136/annrheumdis-2018-213558. Epub 2018 May 5. No abstract available.

PMID:
29730638
11.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e47. doi: 10.1136/annrheumdis-2018-213537. Epub 2018 Apr 28. No abstract available.

PMID:
29705742
12.

Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May;78(5):e34. doi: 10.1136/annrheumdis-2018-213399. Epub 2018 Mar 28. No abstract available.

PMID:
29592916
13.

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Jun;77(6):911-913. doi: 10.1136/annrheumdis-2017-212599. Epub 2018 Feb 9.

PMID:
29440000
14.

ERp57 is protective against mutant SOD1-induced cellular pathology in amyotrophic lateral sclerosis.

Parakh S, Jagaraj CJ, Vidal M, Ragagnin AMG, Perri ER, Konopka A, Toth RP, Galper J, Blair IP, Thomas CJ, Walker AK, Yang S, Spencer DM, Atkin JD.

Hum Mol Genet. 2018 Apr 15;27(8):1311-1331. doi: 10.1093/hmg/ddy041.

PMID:
29409023
15.

The release of microparticles and mitochondria from RAW 264.7 murine macrophage cells undergoing necroptotic cell death in vitro.

Spencer DM, Dye JR, Piantadosi CA, Pisetsky DS.

Exp Cell Res. 2018 Feb 15;363(2):151-159. doi: 10.1016/j.yexcr.2017.12.024. Epub 2017 Dec 29.

PMID:
29291399
16.

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study.

Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N.

Clin Transl Gastroenterol. 2017 Nov 2;8(11):e126. doi: 10.1038/ctg.2017.52.

17.

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.

Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S.

Cancer Discov. 2017 Nov;7(11):1306-1319. doi: 10.1158/2159-8290.CD-17-0263. Epub 2017 Aug 11.

18.

Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.

Foster AE, Mahendravada A, Shinners NP, Chang WC, Crisostomo J, Lu A, Khalil M, Morschl E, Shaw JL, Saha S, Duong MT, Collinson-Pautz MR, Torres DL, Rodriguez T, Pentcheva-Hoang T, Bayle JH, Slawin KM, Spencer DM.

Mol Ther. 2017 Sep 6;25(9):2176-2188. doi: 10.1016/j.ymthe.2017.06.014. Epub 2017 Jul 8.

19.

Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer.

Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, Spencer DM, Slawin KM.

Cancer Immunol Immunother. 2017 Oct;66(10):1345-1357. doi: 10.1007/s00262-017-2027-6. Epub 2017 Jun 12.

PMID:
28608115
20.

Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes.

Ono N, Murakami K, Chan O, Hall H, Elford AR, Yen P, Calzascia T, Spencer DM, Ohashi PS, Dhanji S.

PLoS One. 2017 Mar 3;12(3):e0173176. doi: 10.1371/journal.pone.0173176. eCollection 2017.

21.

MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.

Collinson-Pautz MR, Slawin KM, Levitt JM, Spencer DM.

PLoS One. 2016 Oct 14;11(10):e0164547. doi: 10.1371/journal.pone.0164547. eCollection 2016.

22.

The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration.

Perri ER, Thomas CJ, Parakh S, Spencer DM, Atkin JD.

Front Cell Dev Biol. 2016 Jan 8;3:80. doi: 10.3389/fcell.2015.00080. eCollection 2015. Review.

23.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK.

Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.

24.

Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques.

Barese CN, Felizardo TC, Sellers SE, Keyvanfar K, Di Stasi A, Metzger ME, Krouse AE, Donahue RE, Spencer DM, Dunbar CE.

Stem Cells. 2015 Jan;33(1):91-100. doi: 10.1002/stem.1869.

25.

Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo.

Kemnade JO, Seethammagari M, Collinson-Pautz M, Kaur H, Spencer DM, McCormick AA.

Vaccine. 2014 Jul 16;32(33):4228-33. doi: 10.1016/j.vaccine.2014.04.051. Epub 2014 Jun 9.

26.

The expression of HMGB1 on microparticles from Jurkat and HL-60 cells undergoing apoptosis in vitro.

Spencer DM, Mobarrez F, Wallén H, Pisetsky DS.

Scand J Immunol. 2014 Aug;80(2):101-10. doi: 10.1111/sji.12191.

27.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G.

Blood. 2014 Jun 19;123(25):3895-905. doi: 10.1182/blood-2014-01-551671. Epub 2014 Apr 21.

28.

Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies.

Wu C, Hong SG, Winkler T, Spencer DM, Jares A, Ichwan B, Nicolae A, Guo V, Larochelle A, Dunbar CE.

Mol Ther Methods Clin Dev. 2014 Nov 12;1:14053. doi: 10.1038/mtm.2014.53. eCollection 2014.

29.

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.

Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW.

PLoS One. 2013 Dec 17;8(12):e82742. doi: 10.1371/journal.pone.0082742. eCollection 2013.

30.

FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma.

Carstens JL, Shahi P, Van Tsang S, Smith B, Creighton CJ, Zhang Y, Seamans A, Seethammagari M, Vedula I, Levitt JM, Ittmann MM, Rowley DR, Spencer DM.

Cancer Res. 2014 Jan 15;74(2):609-20. doi: 10.1158/0008-5472.CAN-13-1093. Epub 2013 Dec 4.

31.

The properties of microparticles from RAW 264.7 macrophage cells undergoing in vitro activation or apoptosis.

Spencer DM, Gauley J, Pisetsky DS.

Innate Immun. 2014 Apr;20(3):239-48. doi: 10.1177/1753425913492552. Epub 2013 Jul 9.

32.

Redox regulation in amyotrophic lateral sclerosis.

Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD.

Oxid Med Cell Longev. 2013;2013:408681. doi: 10.1155/2013/408681. Epub 2013 Feb 25. Review.

33.

Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity.

Valdez JM, Zhang L, Su Q, Dakhova O, Zhang Y, Shahi P, Spencer DM, Creighton CJ, Ittmann MM, Xin L.

Cell Stem Cell. 2012 Nov 2;11(5):676-88. doi: 10.1016/j.stem.2012.07.003.

34.

The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.

Harrill AH, Roach J, Fier I, Eaddy JS, Kurtz CL, Antoine DJ, Spencer DM, Kishimoto TK, Pisetsky DS, Park BK, Watkins PB.

Clin Pharmacol Ther. 2012 Aug;92(2):214-20. doi: 10.1038/clpt.2012.40. Epub 2012 Jun 27.

36.

Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Kemnade JO, Seethammagari M, Narayanan P, Levitt JM, McCormick AA, Spencer DM.

Mol Ther. 2012 Jul;20(7):1462-71. doi: 10.1038/mt.2012.48. Epub 2012 Mar 20.

37.

Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis.

Shahi P, Park D, Pond AC, Seethammagari M, Chiou SH, Cho K, Carstens JL, Decker WK, McCrea PD, Ittmann MM, Rosen JM, Spencer DM.

PLoS One. 2012;7(1):e30814. doi: 10.1371/journal.pone.0030814. Epub 2012 Jan 27.

38.

Inducible apoptosis as a safety switch for adoptive cell therapy.

Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK.

N Engl J Med. 2011 Nov 3;365(18):1673-83. doi: 10.1056/NEJMoa1106152.

39.

Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.

Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Spencer DM, Xie X.

J Gene Med. 2011 Dec;13(12):680-91. doi: 10.1002/jgm.1620. Erratum in: J Gene Med. 2012 Mar;14(3):217. Spencer, David M [added].

PMID:
22009763
40.

Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, Lapteva N, Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH.

Nucleic Acid Ther. 2011 Oct;21(5):299-314. doi: 10.1089/nat.2011.0313.

41.

The E3 ligase c-Cbl regulates dendritic cell activation.

Chiou SH, Shahi P, Wagner RT, Hu H, Lapteva N, Seethammagari M, Sun SC, Levitt JM, Spencer DM.

EMBO Rep. 2011 Sep 1;12(9):971-9. doi: 10.1038/embor.2011.143.

42.

Effects of progesterone and estradiol sex hormones on the release of microparticles by RAW 264.7 macrophages stimulated by Poly(I:C).

Pisetsky DS, Spencer DM.

Clin Vaccine Immunol. 2011 Sep;18(9):1420-6. doi: 10.1128/CVI.05110-11. Epub 2011 Jun 8.

43.

A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.

Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM.

J Clin Invest. 2011 Apr;121(4):1524-34. doi: 10.1172/JCI44327. Epub 2011 Mar 7.

44.

The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function.

Ramachandran IR, Song W, Lapteva N, Seethammagari M, Slawin KM, Spencer DM, Levitt JM.

J Immunol. 2011 Apr 1;186(7):3934-45. doi: 10.4049/jimmunol.1001675. Epub 2011 Feb 25.

45.

Wnt and Notch pathways have interrelated opposing roles on prostate progenitor cell proliferation and differentiation.

Shahi P, Seethammagari MR, Valdez JM, Xin L, Spencer DM.

Stem Cells. 2011 Apr;29(4):678-88. doi: 10.1002/stem.606.

46.

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.

Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu MF, Liu H, Kenney S, Gottschalk S.

Blood. 2011 Apr 21;117(16):4304-14. doi: 10.1182/blood-2010-04-278218. Epub 2011 Feb 8.

47.

T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM.

Mol Ther. 2010 Nov;18(11):2006-17. doi: 10.1038/mt.2010.185. Epub 2010 Sep 14.

48.

Death switch for gene therapy: application to erythropoietin transgene expression.

Souza DS, Spencer DM, Salles TS, Salomão MA, Payen E, Beuzard Y, Carvalho HF, Costa FF, Saad ST.

Braz J Med Biol Res. 2010 Jul;43(7):634-44. Epub 2010 May 21.

49.

Emerging vaccine therapy approaches for prostate cancer.

Sonpavde G, Slawin KM, Spencer DM, Levitt JM.

Rev Urol. 2010 Winter;12(1):25-34.

50.

Barminomycin, a model for the development of new anthracyclines.

Kimura K, Spencer DM, Bilardi R, Swift LP, Box AJ, Brownlee RT, Cutts SM, Phillips DR.

Anticancer Agents Med Chem. 2010 Jan;10(1):70-7. Review.

PMID:
19807684

Supplemental Content

Loading ...
Support Center